December 2008
Volume 8, Issue 17
Free
OSA Fall Vision Meeting Abstract  |   December 2008
Stem cell derived retinal pigment Epithelium for the treatment of age-related Macular degeneration
Author Affiliations
  • David E. Buchholz
    Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, CA
  • Sherry T. Hikita
    Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, CA
  • Monte J. Radeke
    Center for the Study of Macular Degeneration, Neuroscience Research Institute, University of California, Santa Barbara, CA
  • Kathryn E. Blashke
    Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, CA
  • Lincoln V. Johnson
    Center For the Study of Macular Degeneration, Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, CA
  • Dennis O. Clegg
    Center For the Study of Macular Degeneration, Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, CA
Journal of Vision December 2008, Vol.8, 47. doi:10.1167/8.17.47
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      David E. Buchholz, Sherry T. Hikita, Monte J. Radeke, Kathryn E. Blashke, Lincoln V. Johnson, Dennis O. Clegg; Stem cell derived retinal pigment Epithelium for the treatment of age-related Macular degeneration. Journal of Vision 2008;8(17):47. doi: 10.1167/8.17.47.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

The retinal pigment epithelium (RPE) works with the rod and cone photoreceptors of the eye to form a functional visual transduction unit. RPE death and dysfunction in age-related macular degeneration (AMD) leads to death of the photoreceptors and loss of vision. AMD is the leading cause of blindness in elderly people in the western world, yet there is currently no cure. Recent studies have shown that autologous transplantations of peripheral RPE to the macula of AMD patients is beneficial. Our lab has derived RPE from human embryonic stem cells (hESC) and induced pluripotent stem cells (iPS), providing a potential source of RPE for transplant. We have focused on characterizing the gene expression, protein expression and cellular function of these stem cell derived RPE. We have also looked at the stability of these cells over multiple passages. Stem cell derived RPE are highly similar to human fetal RPE at low passages, but by passage 5 have changed morphology and gene expression dramatically, resulting in a loss of cellular function. These studies demonstrate that stem cell-RPE is a promising cellular therapy for AMD, although the challenge of scalability still needs to be solved.

Buchholz, D. E. Hikita, S. T. Radeke, M. J. Blashke, K. E. Johnson, L. V. Clegg, D. O. (2008). Stem cell derived retinal pigment Epithelium for the treatment of age-related Macular degeneration [Abstract]. Journal of Vision, 8(17):47, 47a, http://journalofvision.org/8/17/47/, doi:10.1167/8.17.47. [CrossRef]
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×